An Exclusive Interview with Mr.Rodrigo Rodriguez Managing Director & Regional Chief of Takeda Middle East during the 2nd International Middle East Genetic and Metabolic Academy ( MEGMA) symposium Dubai , UAE . The event held from Nov 04,2021-Nov 06,2021.
During the Q& A session Mr. Rodrigo Rodriguez express his complete satisfaction and find it very successful MEGMA symposium. Such Events brings lots of research, ideas , innovation, suggestions, recommendations for the treatment of Genetic and Metabolic diseases. Leading speakers from different Universities , Hospitals and Pharmacuetical Companies present there latest Research Papers.
Since Takeda is among the TOP ten Pharmacuetical companies of the World they emphasis more on research and development. Bringing new and more successful treatment for acute medical treatments.
The most successful and famous treatment from Takeda is for the Gastroenterology or in common term it is Bowl related problems- Gastroenterology and it is a highly specialized and extensive field of medicine that lays stress on the digestive system and related disorders such as peptic ulcer disease, gastric cancers, esophageal cancers, achalasia, Barret’s esophagus, colon polyps, colon and bowel cancers, pancreatitis, pancreatic cancers, cholecystitis, biliary tract disease, gallbladder stones and cancer, hepatitis, gastroesophageal reflux, colitis, nutritional problems .
Regarding the Future outlook Mr. Rodrigo Rodriguez is very positive despite all the odds during the pandemic there was no supply issue of treatment and medicine from Takeda. It all goes smooth.
Finally Mr. Rodrigo Rodriguez foresee a very promising outlook for Takeda generally and in Particular for Middle East.